News & Updates
Filter by Specialty:

Use of 5αRI does not increase cardiovascular risk in men with BPH
Treatment with five-alpha reductase inhibitors (5αRIs) does not appear to elevate the risk of hospitalization for heart failure (HF), myocardial infarction (MI), stroke, or cardiovascular death among men with benign prostatic hyperplasia (BPH), a study has shown.
Use of 5αRI does not increase cardiovascular risk in men with BPH
30 Sep 2023
Lorundrostat may expand treatment toolbox for uncontrolled hypertension
Aldosterone synthase inhibition with lorundrostat confers substantial blood pressure (BP)-lowering benefit in people with uncontrolled hypertension, while having a favourable safety profile, according to data from the phase II Target-HTN trial.
Lorundrostat may expand treatment toolbox for uncontrolled hypertension
29 Sep 2023
Pretreatment serum CEA level predicts survival in NSCLC
Pretreatment level of serum carcinoembryonic antigen (CEA) is independently associated with overall and disease-free survival among patients with nonsmall cell lung cancer (NSCLC), reports a study. The same marker is also used for the prognosis of patients with the same pathologic stages.